人类首次“碱基编辑”试验降低了胆固醇水平，但引发了安全担忧。 - Suppr

Suppr

超能文献

First trial of 'base editing' in humans lowers cholesterol - but raises safety concerns.

作者信息

Naddaf Miryam

出版信息

Nature. 2023 Nov;623(7988):671-672. doi: 10.1038/d41586-023-03543-z.

DOI:10.1038/d41586-023-03543-z

PMID:37957349

Abstract

摘要

相似文献

First trial of 'base editing' in humans lowers cholesterol - but raises safety concerns.

Nature. 2023 Nov;623(7988):671-672. doi: 10.1038/d41586-023-03543-z.

CRISPR babies: when will the world be ready?

Nature. 2019 Jun;570(7761):293-296. doi: 10.1038/d41586-019-01906-z.

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub 2017 Jul 27.

The promise and challenge of therapeutic genome editing.

Nature. 2020 Feb;578(7794):229-236. doi: 10.1038/s41586-020-1978-5. Epub 2020 Feb 12.

The kill-switch for CRISPR that could make gene-editing safer.

Nature. 2020 Jan;577(7790):308-310. doi: 10.1038/d41586-020-00053-0.

Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing.

Mol Genet Metab. 2021 Sep-Oct;134(1-2):117-131. doi: 10.1016/j.ymgme.2021.07.006. Epub 2021 Jul 21.

Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.

Eur J Hum Genet. 2018 Apr;26(4):450-470. doi: 10.1038/s41431-017-0077-z. Epub 2018 Jan 12.

How should the applications of genome editing be assessed and regulated?

Elife. 2017 Apr 4;6:e26295. doi: 10.7554/eLife.26295.

The CRISPR-Cas9 Genome Editing System: Not as Precise as Previously Believed.

World Neurosurg. 2018 Oct;118:377-378. doi: 10.1016/j.wneu.2018.08.042. Epub 2018 Aug 14.

Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.

Mol Genet Metab. 2021 Sep-Oct;134(1-2):77-86. doi: 10.1016/j.ymgme.2021.08.002. Epub 2021 Aug 8.

引用本文的文献

A bioinformatic analysis of gene editing off-target loci altered by common polymorphisms, using 'PopOff'.

J R Soc N Z. 2024 May 9;55(6):2440-2463. doi: 10.1080/03036758.2024.2347968. eCollection 2025.

Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease.

Semin Nephrol. 2025 Jul 11:151651. doi: 10.1016/j.semnephrol.2025.151651.

Gene therapy for cardiac arrhythmias.

Nat Rev Cardiol. 2025 May 23. doi: 10.1038/s41569-025-01168-5.

Current trends in gene therapy to treat inherited disorders of the brain.

Mol Ther. 2025 May 7;33(5):1988-2014. doi: 10.1016/j.ymthe.2025.03.057. Epub 2025 Apr 2.

The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.

Mol Ther. 2025 May 7;33(5):1966-1987. doi: 10.1016/j.ymthe.2025.03.041. Epub 2025 Mar 27.

RNA therapeutics in cardiovascular medicine.

Curr Opin Cardiol. 2025 May 1;40(3):139-149. doi: 10.1097/HCO.0000000000001210. Epub 2025 Feb 18.

RNA-based therapies in liver metabolic diseases.

Gut. 2025 Feb 23. doi: 10.1136/gutjnl-2023-331742.

Multiarm-Assisted Design of Dendron-like Degradable Ionizable Lipids Facilitates Systemic mRNA Delivery to the Spleen.

J Am Chem Soc. 2025 Jan 15;147(2):1542-1552. doi: 10.1021/jacs.4c10265. Epub 2025 Jan 1.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Nat Rev Drug Discov. 2025 Jan;24(1):40-56. doi: 10.1038/s41573-024-01059-3. Epub 2024 Nov 4.

本文引用的文献

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.

N Engl J Med. 2023 Sep 7;389(10):899-910. doi: 10.1056/NEJMoa2300709. Epub 2023 Jun 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

First trial of 'base editing' in humans lowers cholesterol - but raises safety concerns.

Nature. 2023 Nov;623(7988):671-672. doi: 10.1038/d41586-023-03543-z.

CRISPR babies: when will the world be ready?

Nature. 2019 Jun;570(7761):293-296. doi: 10.1038/d41586-019-01906-z.

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub 2017 Jul 27.

The promise and challenge of therapeutic genome editing.

Nature. 2020 Feb;578(7794):229-236. doi: 10.1038/s41586-020-1978-5. Epub 2020 Feb 12.

The kill-switch for CRISPR that could make gene-editing safer.

Nature. 2020 Jan;577(7790):308-310. doi: 10.1038/d41586-020-00053-0.

Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing.

Mol Genet Metab. 2021 Sep-Oct;134(1-2):117-131. doi: 10.1016/j.ymgme.2021.07.006. Epub 2021 Jul 21.

Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.

Eur J Hum Genet. 2018 Apr;26(4):450-470. doi: 10.1038/s41431-017-0077-z. Epub 2018 Jan 12.

How should the applications of genome editing be assessed and regulated?

Elife. 2017 Apr 4;6:e26295. doi: 10.7554/eLife.26295.

The CRISPR-Cas9 Genome Editing System: Not as Precise as Previously Believed.

World Neurosurg. 2018 Oct;118:377-378. doi: 10.1016/j.wneu.2018.08.042. Epub 2018 Aug 14.

Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.

Mol Genet Metab. 2021 Sep-Oct;134(1-2):77-86. doi: 10.1016/j.ymgme.2021.08.002. Epub 2021 Aug 8.

引用本文的文献

A bioinformatic analysis of gene editing off-target loci altered by common polymorphisms, using 'PopOff'.

J R Soc N Z. 2024 May 9;55(6):2440-2463. doi: 10.1080/03036758.2024.2347968. eCollection 2025.

Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease.

Semin Nephrol. 2025 Jul 11:151651. doi: 10.1016/j.semnephrol.2025.151651.

Gene therapy for cardiac arrhythmias.

Nat Rev Cardiol. 2025 May 23. doi: 10.1038/s41569-025-01168-5.

Current trends in gene therapy to treat inherited disorders of the brain.

Mol Ther. 2025 May 7;33(5):1988-2014. doi: 10.1016/j.ymthe.2025.03.057. Epub 2025 Apr 2.

The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.

Mol Ther. 2025 May 7;33(5):1966-1987. doi: 10.1016/j.ymthe.2025.03.041. Epub 2025 Mar 27.

RNA therapeutics in cardiovascular medicine.

Curr Opin Cardiol. 2025 May 1;40(3):139-149. doi: 10.1097/HCO.0000000000001210. Epub 2025 Feb 18.

RNA-based therapies in liver metabolic diseases.

Gut. 2025 Feb 23. doi: 10.1136/gutjnl-2023-331742.

Multiarm-Assisted Design of Dendron-like Degradable Ionizable Lipids Facilitates Systemic mRNA Delivery to the Spleen.

J Am Chem Soc. 2025 Jan 15;147(2):1542-1552. doi: 10.1021/jacs.4c10265. Epub 2025 Jan 1.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Nat Rev Drug Discov. 2025 Jan;24(1):40-56. doi: 10.1038/s41573-024-01059-3. Epub 2024 Nov 4.

本文引用的文献

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.

N Engl J Med. 2023 Sep 7;389(10):899-910. doi: 10.1056/NEJMoa2300709. Epub 2023 Jun 14.